Posted on Feb 22, 2022
We are really pleased to announce that we have signed exclusive distribution agreements with four key European partners in the last month.
We will be working with Italian firm AB Analytica, Omegen Molecular from Istanbul, Romanian firm Diamedix and Buhlmann Labs in Switzerland to distribute MammaTyper© across much of Southern and Central Europe. All of these firms were hand-picked for their breadth of knowledge and expertise. Some we have worked with before and we are delighted that they all share our enthusiasm for bringing innovative technology to women’s health.
MammaTyper© is one of the biggest advancements in breast cancer diagnostics for decades, applying 21st Century RT-qPCR technology to quantify mRNA levels of four essential breast cancer biomarkers (ER, PgR, HER2, and Ki-67). It is quicker, non-subjective and more economically viable than the current methods.
Robustly reproducible, it avoids many of the common pre-analytical errors in the pathology lab, especially for proliferation marker Ki-67 - critical in luminal subtyping and prognosis. Using RT-qPCR to subtype breast cancer tissue is a valuable resource for pathologists and provides the reassurance that accurate subtyping will result in women getting the best treatment for their individual case.
The addition of these key partners brings a wealth of clinical and technical expertise to the MammaTyper© team covering Italy, Austria, Switzerland, Turkey, Romania, Republic of Moldova, Ukraine, Bulgaria and Georgia. This however, is just the start. We have plans to bring MammaTyper© to the Nordics, Germany, the UK and Benelux in the near future and we are actively seeking partners in these regions.
If you’d like to get involved, get in touch with Rich via firstname.lastname@example.org, we’d love to hear from you.